Predictors of intermediate syndrome after organophosphorus poisoning and its management in Nepal

Clinical Predictors

Development of IMS is closely linked to the severity and characteristics of the initial OP poisoning. Severe acute cholinergic symptoms, such as profound muscle fasciculations, seizures, or coma, are strongly associated with IMS risk. The World Health Organization classifies OP compounds by toxicity, with class I agents (e.g., parathion, monocrotophos) posing the highest risk due to their potent AChE inhibition [10]. Studies have shown that patients requiring high doses of atropine or prolonged mechanical ventilation in the acute phase are more likely to develop IMS, likely due to sustained acetylcholine overload [11].

Delayed or inadequate antidote administration significantly increases IMS risk. For instance, failure to administer pralidoxime within 24–48 hours of exposure can lead to persistent AChE inhibition, a key precursor to IMS [12]. Prolonged exposure, such as through large-dose ingestion or dermal contact in occupational settings, also heightens risk by maintaining high OP levels in the body [13]. Specific OP compounds, particularly lipophilic agents like fenthion and dimethoate, are more frequently implicated in IMS due to their slow metabolism and prolonged AChE inhibition [14]. These compounds form stable complexes with AChE, delaying recovery and increasing the likelihood of neuromuscular complications.

Biochemical Predictors

Biochemical markers play a critical role in predicting IMS. Low red blood cell (RBC) AChE activity, typically below 10%–20% of normal at presentation, is a strong predictor of IMS [15]. Persistent AChE inhibition beyond 24 hours, often due to inadequate oxime therapy, further elevates risk [16]. Elevated serum creatine kinase levels, indicative of muscle damage, is common in IMS patients, reflecting myotoxicity from prolonged nicotinic receptor stimulation [17]. Low serum cholinesterase levels also correlate with IMS, serving as an accessible biomarker in resource-limited settings [18].

Electrolyte imbalances, particularly hypokalemia and hypomagnesemia, exacerbate neuromuscular dysfunction and are frequently reported in severe OP poisoning [19]. These imbalances can disrupt muscle membrane stability, contributing to weakness. Additionally, emerging research suggests that oxidative stress markers, such as elevated malondialdehyde levels, can predict IMS by indicating cellular damage from OP exposure [20]. Regular monitoring of these biochemical parameters in the first 48 hours post-poisoning can aid in risk stratification and guide therapeutic decisions.

Electrophysiological Predictors

Electrophysiological studies provide valuable insights into IMS risk. Repetitive compound muscle action potentials following a single stimulus on nerve conduction studies indicate prolonged neuromuscular junction dysfunction, a hallmark of IMS [21]. A decremental response on repetitive nerve stimulation (RNS) at low frequencies (3–5 Hz) is a reliable early indicator of the syndrome, often detectable before clinical symptoms [22]. Single-fiber electromyography reveals increased jitter and blockage, reflecting impaired neuromuscular transmission, and is particularly useful in high-risk patients [4]. Early identification of these electrophysiological abnormalities allow clinicians to anticipate IMS and initiate preventive measures. However, access to such diagnostic tools is often limited in low-resource settings, underscoring the need for portable, cost-effective alternatives.

Patient-Related Factors

Patient-specific factors influence IMS susceptibility. Elderly patients or those with pre-existing neuromuscular disorders are at higher risk due to reduced physiological reserve [23]. Malnutrition, prevalent in rural populations where use of OP pesticides is common, exacerbates muscle weakness and delays recovery [24]. Additionally, genetic variations in enzymes like paraoxonase-1, which detoxify OP compounds, can modulate IMS risk, though evidence remains preliminary [25]. These factors highlight the importance of a holistic approach to risk assessment, considering both environmental and patient-specific variables.

Early Recognition and Monitoring

Early recognition of IMS is critical to prevent fatal outcomes. Patients with severe OP poisoning should be monitored in an intensive care unit (ICU) for 72–96 hours for signs of IMS, such as neck flexor weakness, cranial nerve palsies, or respiratory distress [27]. Regular clinical assessments, including muscle strength testing, are essential. Electrophysiological monitoring, particularly RNS and nerve conduction studies, can detect subclinical neuromuscular dysfunction, enabling preemptive intervention [21]. Serial measurement of RBC AChE and serum creatine kinase levels provides additional prognostic value [15,17]. In resource-limited settings, where electrophysiological tools might be unavailable, clinical vigilance and biochemical monitoring are critical for identifying at-risk patients.

Pharmacological Management

Atropine remains the cornerstone of management for acute OP poisoning, targeting muscarinic symptoms but offering limited protection against IMS [1]. An initial loading dose of 1.8–3.6 mg is rapidly administered via intravenous push. If atropinization does not occur within 3–5 minutes, the dose is doubled at that time interval until the patient is fully atropinized. The infusion is maintained at 10%–20% of the total loading dose/hour intravenously, continued until cholinergic signs resolve (typically 24–48 hours), and then tapered as the symptoms improve [28].

Oximes, such as pralidoxime or obidoxime, are critical for reactivating AChE and reducing IMS risk if administered within 24–48 hours. For severe cases, the recommended loading dose is 30 mg/kg of IV pralidoxime over 10–20 minutes, followed by a continuous infusion of 8–10 mg/kg per hour until clinical recovery. However, the efficacy of this treatment is lower for lipophilic OPs [29]. Once IMS develops, atropine is not needed unless cholinergic symptoms recur due to ongoing absorption or re-distribution. Oxime therapy is not associated with improved survival once IMS develops, and continued oxime use can prolong neuromuscular weakness [4].

Adjunctive therapies, such as magnesium sulfate, administered as 4 g IV over 24 hours, show promise in stabilizing neuromuscular junctions and reducing excitotoxicity, with clinical trials reporting improved outcomes [30]. Supportive therapies, including correction of hypokalemia and hypomagnesemia, are essential to prevent exacerbation of muscle weakness [19]. Nutritional support, particularly in malnourished patients, aids recovery and reduces complications [24].

Respiratory Support

Respiratory failure is the leading cause of death in IMS and requires prompt intervention. Non-invasive ventilation can be effective in patients with early respiratory compromise, delaying or preventing intubation [31]. However, severe IMS often requires intubation and mechanical ventilation, with weaning guided by clinical and electrophysiological recovery [32]. Short-acting or intermediate-acting non-depolarizing agents, such as vecuronium or atracurium, should be used to facilitate intubation and mechanical ventilation. Succinylcholine should be avoided due to unpredictable response from low plasma cholinesterase activity. The lowest effective doses should be used and titrated by train-of-four monitoring to prevent prolonged weakness. Close monitoring of respiratory muscle strength and arterial blood gases is critical to optimize ventilatory support. In resource-constrained settings, where ventilators are scarce, prioritizing early non-invasive ventilation and manual ventilation strategies can be lifesaving.

Emerging Therapies

Emerging therapies show potential in IMS management. Antioxidants, such as N-acetylcysteine or vitamin C, can mitigate oxidative stress and reduce IMS severity, though evidence is preliminary [20]. Neuromuscular junction stabilizers, like 3,4-diaminopyridine, are under investigation for enhancing neuromuscular transmission, but robust clinical data are lacking [33]. Research into novel AChE reactivators, designed to target lipophilic OPs, is ongoing and could lead to improvement in outcomes [34].

Long-Term Management and Prevention

Post-IMS recovery requires physical therapy to restore muscle strength and prevent contractures [4]. Education on safe pesticide use, including personal protective equipment, is essential to prevent recurrent exposures, particularly in agricultural communities [35]. Public health campaigns and regulatory measures to restrict highly toxic OP compounds can further reduce IMS incidence. Long-term follow-up is necessary to monitor delayed neuropathy and other sequelae.